10 results
First, to demonstrate whether UDCA-therapy is effective in reducing total liver volume in PLD patients. Second, we want to assess if UDCA modifies quality of life. Finally, we want to assess safety and tolerability.
1) Study the chemopreventive potential of 5-ASA and UDCA in UC by evaluating the effect of treatment on ACF number, size and rate of dysplasia, relative to the placebo group. 2) Gain mechanistic insight into the chemopreventive properties of 5-ASA…
To compare the efficacy and tolerability of a combination therapy with ursodeoxycholic acid (12-16 mg/kg body weight plus budesonide (9mg/d) vs. ursodeoxycholic acid (12-16 mg/kg BW/d) plus placebo in the treatment of PBC. To study safety and…
In the Netherlands, approximately 500 patients with FAP have been recognized, who are at high risk for developing duodenal carcinoma. Better insights in the pathogenesis of duodenal cancer and development of chemoprevention strategies are of pivotal…
1) Study the chemopreventive potential of 5-ASA and UDCA in UC by evaluating the effect of treatment with these agents on ACF number, size and rate of dysplasia. 2) Gain mechanistic insight into the chemopreventive properties of 5-ASA and UDCA by…
To assess the bile acid composition of cystic bile and serum pharmacokinetics after a 3-week treatment with UDCA and to correlate pharmacokinetic parameter sof UDCA in bile and serum during steady state.To compare the composition of bile acids and…
Does antagonism of the adenosine receptor by caffeine lead to an increased LPS-induced inflammatory reaction and an increase in (subclinical) tissuedamage?Does the C34T-polymorphism of the enzyme AMP-deaminase lead to a decreased inflammatory…
Primary ObjectiveThe primary objective is to evaluate the effectiveness of adding Epanova to statin therapy (with or without ezetimibe) for lowering MACE (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, emergent/elective…
The primary objective is to evaluate the effect of UDCA and ezetimibe on cholesterol elimination assessed as total faecal sterol concentration. Secondary objective is to assess the effect of UDCA and ezetimibe on plasma lipid profile/composition.
This study is designed to provide evidence regarding the prophylactic use of UDCA in preventing symptomatic gallstone disease after RYGB and Sleeve Gastrectomy.